{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T07:17:28Z","timestamp":1775200648956,"version":"3.50.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP23K15739"],"award-info":[{"award-number":["JP23K15739"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP25H01219"],"award-info":[{"award-number":["JP25H01219"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"crossref","award":["JPMJCR22L5"],"award-info":[{"award-number":["JPMJCR22L5"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Syst Biol Appl"],"DOI":"10.1038\/s41540-026-00668-5","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T13:34:07Z","timestamp":1771421647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In silico exploration of osteoclast precursor inhibition for preventing rapid bone loss after denosumab discontinuation"],"prefix":"10.1038","volume":"12","author":[{"given":"Young Kwan","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Kameo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakae","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiji","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"668_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ar.1092260402","volume":"226","author":"HM Frost","year":"1990","unstructured":"Frost, H. M. Skeletal structural adaptations to mechanical usage (SATMU): 1. Redefining Wolff\u2019s law: the bone modeling problem. Anat. Rec. 226, 403\u2013413 (1990).","journal-title":"Anat. Rec."},{"key":"668_CR2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/ar.1092260403","volume":"226","author":"HM Frost","year":"1990","unstructured":"Frost, H. M. Skeletal structural adaptations to mechanical usage (SATMU): 2. Redefining Wolff\u2019s law: the remodeling problem. Anat. Rec. 226, 414\u2013422 (1990).","journal-title":"Anat. Rec."},{"key":"668_CR3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston, J. E., McClung, M. R. & Leslie, W. D. Osteoporosis. Lancet 393, 364\u2013376 (2019).","journal-title":"Lancet"},{"key":"668_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-020-0706-y","volume":"15","author":"F Borgstrom","year":"2020","unstructured":"Borgstrom, F. et al. International Osteoporosis Foundation, Fragility fractures in Europe: burden, management and opportunities. Arch. Osteoporos. 15, 59 (2020).","journal-title":"Arch. Osteoporos."},{"key":"668_CR5","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00198-020-05334-y","volume":"31","author":"EM Lewiecki","year":"2020","unstructured":"Lewiecki, E. M. et al. Osteoporotic fracture trends in a population of US managed care enrollees from 2007 to 2017. Osteoporos. Int. 31, 1299\u20131304 (2020).","journal-title":"Osteoporos. Int."},{"key":"668_CR6","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1359\/JBMR.040305","volume":"19","author":"PJ Bekker","year":"2004","unstructured":"Bekker, P. J. et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Min. Res. 19, 1059\u20131066 (2004).","journal-title":"J. Bone Min. Res."},{"key":"668_CR7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung, M. R. et al. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354, 821\u2013831 (2006).","journal-title":"N. Engl. J. Med."},{"key":"668_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bone.2011.03.769","volume":"49","author":"PJ Kostenuik","year":"2011","unstructured":"Kostenuik, P. J. et al. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone 49, 151\u2013161 (2011).","journal-title":"Bone"},{"key":"668_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/1759720X16670154","volume":"8","author":"B Langdahl","year":"2016","unstructured":"Langdahl, B., Ferrari, S. & Dempster, D. W. Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Ther. Adv. Musculoskeletal Dis. 8, 225\u2013235 (2016).","journal-title":"Ther. Adv. Musculoskeletal Dis."},{"key":"668_CR10","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/jbmr.2480","volume":"30","author":"MS Ominsky","year":"2015","unstructured":"Ominsky, M. S. et al. Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab. J. Bone Min. Res. 30, 1280\u20131289 (2015).","journal-title":"J. Bone Min. Res."},{"key":"668_CR11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/jbmr.3309","volume":"33","author":"DW Dempster","year":"2018","unstructured":"Dempster, D. W. et al. Remodeling- and modeling-based bone formation with teriparatide versus denosumab: a longitudinal analysis from baseline to 3 months in the AVA study. J. Bone Min. Res. 33, 298\u2013306 (2018).","journal-title":"J. Bone Min. Res."},{"key":"668_CR12","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/jbmr.4006","volume":"35","author":"DW Dempster","year":"2020","unstructured":"Dempster, D. W. et al. Modeling-based bone formation in the human femoral neck in subjects treated with denosumab. J. Bone Min. Res. 35, 1282\u20131288 (2020).","journal-title":"J. Bone Min. Res."},{"key":"668_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756\u2013765 (2009).","journal-title":"N. Engl. J. Med."},{"key":"668_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone, H. G. et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diab. Endocrinol. 5, 513\u2013523 (2017).","journal-title":"Lancet Diab. Endocrinol."},{"key":"668_CR15","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone, H. G. et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab. 96, 972\u2013980 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"668_CR16","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","volume":"28","author":"MR McClung","year":"2017","unstructured":"McClung, M. R., Wagman, R. B., Miller, P. D., Wang, A. & Lewiecki, E. M. Observations following discontinuation of long-term denosumab therapy. Osteoporos. Int. 28, 1723\u20131732 (2017).","journal-title":"Osteoporos. Int."},{"key":"668_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00784-015-1550-0","volume":"20","author":"S Kuroshima","year":"2016","unstructured":"Kuroshima, S., Al-Salihi, Z. & Yamashita, J. Mouse anti-RANKL antibody delays oral wound healing and increases TRAP-positive mononuclear cells in bone marrow. Clin. Oral. Investig. 20, 727\u2013736 (2016).","journal-title":"Clin. Oral. Investig."},{"key":"668_CR18","doi-asserted-by":"publisher","unstructured":"Anastasilakis, A. D. et al. Denosumab discontinuation and the rebound phenomenon: a narrative review. J. Clin. Med. 10 https:\/\/doi.org\/10.3390\/jcm10010152 (2021).","DOI":"10.3390\/jcm10010152"},{"key":"668_CR19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11914-022-00756-5","volume":"20","author":"AS Kim","year":"2022","unstructured":"Kim, A. S., Girgis, C. M. & McDonald, M. M. Osteoclast recycling and the rebound phenomenon following denosumab discontinuation. Curr. Osteoporos. Rep. 20, 505\u2013515 (2022).","journal-title":"Curr. Osteoporos. Rep."},{"key":"668_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/jbmr\/zjae170","volume":"40","author":"M Schini","year":"2024","unstructured":"Schini, M. et al. The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation. J. Bone Miner. Res. 40, 301\u2013306 (2024).","journal-title":"J. Bone Miner. Res."},{"key":"668_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings, S. R. et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J. Bone Min. Res. 33, 190\u2013198 (2018).","journal-title":"J. Bone Min. Res."},{"key":"668_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","volume":"106","author":"E Tsourdi","year":"2021","unstructured":"Tsourdi, E. et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J. Clin. Endocrinol. Metab. 106, 264\u2013281 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"668_CR23","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","volume":"105","author":"D Kendler","year":"2020","unstructured":"Kendler, D. et al. Bone mineral density after transitioning from denosumab to alendronate. J. Clin. Endocrinol. Metab. 105, e255\u2013e264 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"668_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1530\/EJE-21-0157","volume":"185","author":"G Grassi","year":"2021","unstructured":"Grassi, G. et al. Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence. Eur. J. Endocrinol. 185, 387\u2013396 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"668_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","volume":"34","author":"T Tutaworn","year":"2023","unstructured":"Tutaworn, T. et al. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study. Osteoporos. Int. 34, 573\u2013584 (2023).","journal-title":"Osteoporos. Int."},{"key":"668_CR26","doi-asserted-by":"publisher","first-page":"115850","DOI":"10.1016\/j.bone.2021.115850","volume":"145","author":"PR Jensen","year":"2021","unstructured":"Jensen, P. R., Andersen, T. L., Chavassieux, P., Roux, J. P. & Delaisse, J. M. Bisphosphonates impair the onset of bone formation at remodeling sites. Bone 145, 115850 (2021).","journal-title":"Bone"},{"key":"668_CR27","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/sj.emboj.7600104","volume":"23","author":"MC Bassik","year":"2004","unstructured":"Bassik, M. C., Scorrano, L., Oakes, S. A., Pozzan, T. & Korsmeyer, S. J. Phosphorylation of BCL-2 regulates ER Ca2+ homeostasis and apoptosis. EMBO J. 23, 1207\u20131216 (2004).","journal-title":"EMBO J."},{"key":"668_CR28","doi-asserted-by":"publisher","first-page":"24546","DOI":"10.1074\/jbc.M800434200","volume":"283","author":"JE Otero","year":"2008","unstructured":"Otero, J. E. et al. Defective osteoclastogenesis by IKKbeta-null precursors is a result of receptor activator of NF-kappaB ligand (RANKL)-induced JNK-dependent apoptosis and impaired differentiation. J. Biol. Chem. 283, 24546\u201324553 (2008).","journal-title":"J. Biol. Chem."},{"key":"668_CR29","doi-asserted-by":"publisher","first-page":"e0142519","DOI":"10.1371\/journal.pone.0142519","volume":"10","author":"W Liu","year":"2015","unstructured":"Liu, W. et al. Osteoprotegerin induces apoptosis of osteoclasts and osteoclast precursor cells via the Fas\/Fas ligand pathway. PLoS ONE 10, e0142519 (2015).","journal-title":"PLoS ONE"},{"key":"668_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s10020-022-00449-w","volume":"28","author":"D Ke","year":"2022","unstructured":"Ke, D., Yu, Y., Li, C., Han, J. & Xu, J. Phosphorylation of BCL2 at the Ser70 site mediates RANKL-induced osteoclast precursor autophagy and osteoclastogenesis. Mol. Med. 28, 22 (2022).","journal-title":"Mol. Med."},{"key":"668_CR31","doi-asserted-by":"publisher","first-page":"100176","DOI":"10.1016\/j.bea.2025.100176","volume":"9","author":"Y Kameo","year":"2025","unstructured":"Kameo, Y., Imai, K., Miya, Y., Kim, Y. K. & Adachi, T. In silico model of mechano-biochemical bone remodeling characterizes the therapeutic effects of osteoporosis drugs depending on the action mechanism. Biomed. Eng. Adv. 9, 100176 (2025).","journal-title":"Biomed. Eng. Adv."},{"key":"668_CR32","doi-asserted-by":"publisher","first-page":"eaax0938","DOI":"10.1126\/sciadv.aax0938","volume":"6","author":"Y Kameo","year":"2020","unstructured":"Kameo, Y., Miya, Y., Hayashi, M., Nakashima, T. & Adachi, T. In silico experiments of bone remodeling explore metabolic diseases and their drug treatment. Sci. Adv. 6, eaax0938 (2020).","journal-title":"Sci. Adv."},{"key":"668_CR33","first-page":"ziad003","volume":"8","author":"YK Kim","year":"2024","unstructured":"Kim, Y. K., Kameo, Y., Tanaka, S. & Adachi, T. Aging effects on osteoclast progenitor dynamics affect variability in bone turnover via feedback regulation. JBMR 8, ziad003 (2024).","journal-title":"JBMR"},{"key":"668_CR34","doi-asserted-by":"publisher","first-page":"886579","DOI":"10.3389\/fbioe.2022.886579","volume":"10","author":"J Mart\u00ednez-Reina","year":"2022","unstructured":"Mart\u00ednez-Reina, J., Calvo-Gallego, J. L., Martin, M. & Pivonka, P. Assessment of strategies for safe drug discontinuation and transition of denosumab treatment in PMO-insights from a mechanistic PK\/PD model of bone turnover. Front. Bioeng. Biotechnol. 10, 886579 (2022).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"668_CR35","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1074\/jbc.M705092200","volume":"283","author":"AG Robling","year":"2008","unstructured":"Robling, A. G. et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin. J. Biol. Chem. 283, 5866\u20135875 (2008).","journal-title":"J. Biol. Chem."},{"key":"668_CR36","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","volume":"20","author":"T Suda","year":"1999","unstructured":"Suda, T. et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20, 345\u2013357 (1999).","journal-title":"Endocr. Rev."},{"key":"668_CR37","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.tem.2012.05.005","volume":"23","author":"T Nakashima","year":"2012","unstructured":"Nakashima, T., Hayashi, M. & Takayanagi, H. New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol. Metab. 23, 582\u2013590 (2012).","journal-title":"Trends Endocrinol. Metab."},{"key":"668_CR38","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/jbmr.5650050402","volume":"5","author":"EF Eriksen","year":"1990","unstructured":"Eriksen, E. F. et al. Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J. Bone Min. Res. 5, 311\u2013319 (1990).","journal-title":"J. Bone Min. Res."},{"key":"668_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00109-013-1084-3","volume":"92","author":"JL Crane","year":"2014","unstructured":"Crane, J. L. & Cao, X. Function of matrix IGF-1 in coupling bone resorption and formation. J. Mol. Med. 92, 107\u2013115 (2014).","journal-title":"J. Mol. Med."},{"key":"668_CR40","doi-asserted-by":"publisher","unstructured":"Giner, M. et al. Circulating osteogenic progenitor cells enhanced with teriparatide or denosumab treatment. J. Clin. Med. 11 https:\/\/doi.org\/10.3390\/jcm11164749 (2022).","DOI":"10.3390\/jcm11164749"},{"key":"668_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41413-025-00433-0","volume":"13","author":"K Ishikawa","year":"2025","unstructured":"Ishikawa, K. et al. Mouse model of anti-RANKL discontinuation reveals reduced bone mass and quality through disruption of bone remodeling. Bone Res. 13, 56 (2025).","journal-title":"Bone Res."},{"key":"668_CR42","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.4335","volume":"36","author":"P Burckhardt","year":"2021","unstructured":"Burckhardt, P., Faouzi, M., Buclin, T. & Lamy, O. Fractures after denosumab discontinuation: a retrospective study of 797 cases. J. Bone Min. Res. 36, 1717\u20131728 (2021).","journal-title":"J. Bone Min. Res."},{"key":"668_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0390-5","volume":"14","author":"M Weichhaus","year":"2015","unstructured":"Weichhaus, M., Chung, S. T. M. & Connelly, L. Osteoprotegerin in breast cancer: beyond bone remodeling. Mol. Cancer 14, 117 (2015).","journal-title":"Mol. Cancer"},{"key":"668_CR44","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41420-022-01042-0","volume":"8","author":"Y Wang","year":"2022","unstructured":"Wang, Y., Liu, Y., Huang, Z., Chen, X. & Zhang, B. The roles of osteoprotegerin in cancer, far beyond a bone player. Cell Death Discov. 8, 252 (2022).","journal-title":"Cell Death Discov."},{"key":"668_CR45","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","volume":"184","author":"MM McDonald","year":"2021","unstructured":"McDonald, M. M. et al. Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell 184, 1330\u20131347.e1313 (2021).","journal-title":"Cell"},{"key":"668_CR46","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S8756-3282(02)00735-4","volume":"30","author":"AM Parfitt","year":"2002","unstructured":"Parfitt, A. M. Misconceptions (2): turnover is always higher in cancellous than in cortical bone. Bone 30, 807\u2013809 (2002).","journal-title":"Bone"},{"key":"668_CR47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.bone.2017.07.023","volume":"105","author":"F Johannesdottir","year":"2017","unstructured":"Johannesdottir, F. et al. Comparison of non-invasive assessments of strength of the proximal femur. Bone 105, 93\u2013102 (2017).","journal-title":"Bone"},{"key":"668_CR48","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/bonekey.2016.77","volume":"5","author":"\u00c5 Bj\u00f8rnerem","year":"2016","unstructured":"Bj\u00f8rnerem, \u00c5 The clinical contribution of cortical porosity to fragility fractures. Bonekey Rep. 5, 846 (2016).","journal-title":"Bonekey Rep."},{"key":"668_CR49","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1002\/jbmr.2855","volume":"31","author":"R Zebaze","year":"2016","unstructured":"Zebaze, R. et al. Denosumab reduces cortical porosity of the proximal femoral shaft in postmenopausal women with osteoporosis. J. Bone Min. Res 31, 1827\u20131834 (2016).","journal-title":"J. Bone Min. Res"},{"key":"668_CR50","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.bone.2017.03.042","volume":"99","author":"R Zebaze","year":"2017","unstructured":"Zebaze, R. et al. Increased cortical porosity is associated with daily, not weekly, administration of equivalent doses of teriparatide. Bone 99, 80\u201384 (2017).","journal-title":"Bone"},{"key":"668_CR51","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.bone.2008.03.025","volume":"43","author":"P Pivonka","year":"2008","unstructured":"Pivonka, P. et al. Model structure and control of bone remodeling: a theoretical study. Bone 43, 249\u2013263 (2008).","journal-title":"Bone"},{"key":"668_CR52","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10928-011-9224-2","volume":"38","author":"S Schmidt","year":"2011","unstructured":"Schmidt, S., Post, T. M., Peletier, L. A., Boroujerdi, M. A. & Danhof, M. Coping with time scales in disease systems analysis: application to bone remodeling. J. Pharmacokinet. Pharmacodyn. 38, 873\u2013900 (2011).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"668_CR53","doi-asserted-by":"publisher","first-page":"14043","DOI":"10.1038\/boneres.2014.43","volume":"2","author":"S Tanaka","year":"2014","unstructured":"Tanaka, S. et al. New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide. Bone Res. 2, 14043 (2014).","journal-title":"Bone Res."},{"key":"668_CR54","doi-asserted-by":"publisher","first-page":"e76228","DOI":"10.7554\/eLife.76228","volume":"11","author":"DJ J\u00f6rg","year":"2022","unstructured":"J\u00f6rg, D. J. et al. Modeling osteoporosis to design and optimize pharmacological therapies comprising multiple drug types. eLife 11, e76228 (2022).","journal-title":"eLife"},{"key":"668_CR55","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1042\/bj0070471","volume":"7","author":"AV Hill","year":"1913","unstructured":"Hill, A. V. The combinations of haemoglobin with oxygen and with carbon monoxide. I. Biochem J. 7, 471\u2013480 (1913).","journal-title":"Biochem J."},{"key":"668_CR56","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jbmr.1805","volume":"28","author":"DW Dempster","year":"2013","unstructured":"Dempster, D. W. et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Min. Res. 28, 2\u201317 (2013).","journal-title":"J. Bone Min. Res."},{"key":"668_CR57","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00198-022-06523-7","volume":"34","author":"F Marini","year":"2023","unstructured":"Marini, F., Giusti, F., Palmini, G. & Brandi, M. L. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders. Osteoporos. Int 34, 213\u2013238 (2023).","journal-title":"Osteoporos. Int"},{"key":"668_CR58","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey, D. L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165\u2013176 (1998).","journal-title":"Cell"},{"key":"668_CR59","doi-asserted-by":"publisher","first-page":"e25900","DOI":"10.1371\/journal.pone.0025900","volume":"6","author":"AR Wijenayaka","year":"2011","unstructured":"Wijenayaka, A. R. et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE 6, e25900 (2011).","journal-title":"PLoS ONE"},{"key":"668_CR60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nature11000","volume":"485","author":"M Hayashi","year":"2012","unstructured":"Hayashi, M. et al. Osteoprotection by semaphorin 3A. Nature 485, 69\u201374 (2012).","journal-title":"Nature"},{"key":"668_CR61","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3233\/ISB-180470","volume":"13","author":"DA Charlebois","year":"2019","unstructured":"Charlebois, D. A. & Balazsi, G. Modeling cell population dynamics. Silico Biol. 13, 21\u201339 (2019).","journal-title":"Silico Biol."},{"key":"668_CR62","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/0221-8747(84)90066-3","volume":"5","author":"EF Eriksen","year":"1984","unstructured":"Eriksen, E. F., Gundersen, H. J., Melsen, F. & Mosekilde, L. Reconstruction of the formative site in iliac trabecular bone in 20 normal individuals employing a kinetic model for matrix and mineral apposition. Metab. Bone Dis. Relat. Res. 5, 243\u2013252 (1984).","journal-title":"Metab. Bone Dis. Relat. Res."},{"key":"668_CR63","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00198-009-1129-1","volume":"21","author":"P D\u2019Amelio","year":"2010","unstructured":"D\u2019Amelio, P. et al. Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos. Int. 21, 1741\u20131750 (2010).","journal-title":"Osteoporos. Int."},{"key":"668_CR64","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1002\/jcp.26587","volume":"233","author":"N Ding","year":"2018","unstructured":"Ding, N. et al. Alendronate induces osteoclast precursor apoptosis via peroxisomal dysfunction mediated ER stress. J. Cell Physiol. 233, 7415\u20137423 (2018).","journal-title":"J. Cell Physiol."},{"key":"668_CR65","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1056\/NEJMoa0802633","volume":"360","author":"RS Weinstein","year":"2009","unstructured":"Weinstein, R. S., Roberson, P. K. & Manolagas, S. C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N. Engl. J. Med. 360, 53\u201362 (2009).","journal-title":"N. Engl. J. Med."},{"key":"668_CR66","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bone.2013.10.024","volume":"59","author":"B Jobke","year":"2014","unstructured":"Jobke, B., Milovanovic, P., Amling, M. & Busse, B. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients. Bone 59, 37\u201343 (2014).","journal-title":"Bone"},{"key":"668_CR67","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00223-011-9473-5","volume":"88","author":"B Eslami","year":"2011","unstructured":"Eslami, B., Zhou, S., Van Eekeren, I., LeBoff, M. S. & Glowacki, J. Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate. Calcif. Tissue Int. 88, 272\u2013280 (2011).","journal-title":"Calcif. Tissue Int."},{"key":"668_CR68","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/0021-9991(88)90002-2","volume":"79","author":"S Osher","year":"1988","unstructured":"Osher, S. & Sethian, J. A. Fronts propagating with curvature-dependent speed: algorithms based on Hamilton-Jacobi formulations. J. Comput. Phys. 79, 12\u201349 (1988).","journal-title":"J. Comput. Phys."},{"key":"668_CR69","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s10237-017-0914-6","volume":"16","author":"YK Kim","year":"2017","unstructured":"Kim, Y. K., Kameo, Y., Tanaka, S. & Adachi, T. Capturing microscopic features of bone remodeling into a macroscopic model based on biological rationales of bone adaptation. Biomech. Model Mechanobiol. 16, 1697\u20131708 (2017).","journal-title":"Biomech. Model Mechanobiol."}],"container-title":["npj Systems Biology and Applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00668-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00668-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00668-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:03:00Z","timestamp":1775192580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41540-026-00668-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["668"],"URL":"https:\/\/doi.org\/10.1038\/s41540-026-00668-5","relation":{},"ISSN":["2056-7189"],"issn-type":[{"value":"2056-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the PDF version of this article, there was a rendering issue in Equation 7, which has now been corrected.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}